Reviewer's report

Title: Administration of Zoledronic Acid Enhances the Effects of Docetaxel on Growth of Prostate Cancer in the Bone Environment

Version: 1 Date: 6 December 2005

Reviewer: Allan Lipton

Reviewer's report:

The enclosed article by Brubaker et al is a study of zoledronic acid alone, Taxotere alone or the combination of the two drugs on a SCID model of prostate cancer. The results are provocative in that in vivo the combination of the two drugs appears to be superior to each alone. I do not have any major comments to make. I believe the manuscript is worthy of publication in your journal.